Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials).

[1]  R. Califf,et al.  Antibodies to Platelet Factor 4/Heparin are Associated with Elevated Endothelial Cell Activation Markers in Patients with Acute Coronary Ischemic Syndromes , 2004, Journal of Thrombosis and Thrombolysis.

[2]  K. Kario,et al.  Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. , 2005, Thrombosis research.

[3]  T. L. Pinto,et al.  Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. , 2004, The American journal of cardiology.

[4]  E. Antman,et al.  The Smoker's Paradox: Insights from the Angiographic Substudies of the TIMI Trials , 2002, Journal of Thrombosis and Thrombolysis.

[5]  Á. Avezum,et al.  Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE) , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  R. Califf,et al.  Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. , 2003, Journal of the American College of Cardiology.

[7]  H. White,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes , 2002, The Lancet.

[8]  H. White,et al.  Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction. , 2002, The American journal of cardiology.

[9]  H. Heidbuchel,et al.  Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial , 2002, Circulation.

[10]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[11]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[12]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[13]  Ş. Kirazlı,et al.  Thrombopoietin and mean platelet volume in coronary artery disease , 2001, Clinical cardiology.

[14]  S. Yusuf,et al.  Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Study , 2001, Circulation.

[15]  A. Skene,et al.  Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.

[16]  C. Ho,et al.  Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. , 1999, The Journal of laboratory and clinical medicine.

[17]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[18]  John F. Martin,et al.  A role for changes in platelet production in the cause of acute coronary syndromes. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[20]  E. Braunwald,et al.  Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. , 1998, Circulation.

[21]  B. Lüderitz,et al.  Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. , 1998, European heart journal.

[22]  E. Braunwald,et al.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.

[23]  E. Antman.  Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.

[24]  B. Bain.  Ethnic and sex differences in the total and differential white cell count and platelet count. , 1996, Journal of clinical pathology.

[25]  C. Cannon,et al.  Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.

[26]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[27]  S. Cobbe.  Thrombolysis in myocardial infarction , 1994, BMJ.

[28]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[29]  E. Trowbridge,et al.  The Platelet Volume Distribution: A Signature of the Prethrombotic State in Coronary Heart Disease? , 1987, Thrombosis and Haemostasis.